Bordetella pertussis (Pertussis) and Other Bordetella Species

Principles and Practice of Pediatric Infectious Diseases, Fourth Edition

Volumn , Issue , 2012, Pages 865-873.e5

  Long, Sarah S ^a,b   Edwards, Kathryn M ^c,d   Mertsola, Jussi ^e  

^a DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

^b ST CHRISTOPHER'S HOSPITAL FOR CHILDREN   (United States)

^c VANDERBILT UNIVERSITY   (United States)

^d MONROE CARELL JR CHILDREN S HOSPITAL AT VANDERBILT   (United States)

^e TURKU UNIVERSITY HOSPITAL   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84966989744     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-1-4377-2702-9.00164-1     Document Type: Chapter

References (162)

1. SS Long, MC Fisher, JE Mortensen, et al. (1990) Epidemiology of pertussis in Philadelphia. CR Manclark,(Eds) Proceedings of the Sixth International Symposium on Pertussis Bethesda, MD: Department of Health and Human Services 335-342.
2. CDC Christie, ML Marx, CD Marchant, et al. (1994) The 1993 epidemic of pertussis in Cincinnati: resurgence of disease in a highly immunized population of children. N Engl J Med 331 16-21.
3. M Heininger, K Stehr, S Schmitt-Grohe, et al. (1994) Clinical characteristics of illness caused by Bordetella parapertussis compared with illness caused by Bordetella pertussis. Pediatr Infect Dis J 13 306-309.
4. P Mastrantonio, P Stefanelli, M Giuliano, et al. (1998) Bordetella parapertussis infection in children: epidemiology, clinical symptoms, and molecular characteristics of isolates. J Clin Microbiol 36 999-1002.
5. JE Hoppe (1999) Update on respiratory infection caused by Bordetella parapertussis. Pediatr Infect Dis J 18 375-381.
6. Q He, MK Viljanen, H Arvilommi, et al. (1998) Whooping cough caused by Bordetella pertussis and Bordetella parapertussis in an immunized population. JAMA 280 635-637.
7. BA Roth, KB Register, J Walt, et al. (2008) Bordetella bronchiseptica pneumonia in an immunocompetent infant and genetic comparison of clinical isolates with kennel cough vaccine strains. Clin Infect Dis 46 905-908.
8. D Wernli, S Emonet, J Schrenzel and S Harbath (2011) Evaluation of eight cases of confirmed Bordetella bronchiseptica infection and colonization over a 15-year period. Clin Microbiol Infect 17 201-203.
9. T Spilker, AA Liwienski and JJ LiPuma (2008) Identification of Bordetella spp. with cystic fibrosis. Clin Microbiol Infect 14 504-506.
10. Y-W Tang, MK Hopkins and CP Kolbert (1998) Bordetella holmesii-like organisms associated with septicemia, endocarditis, and respiratory failure. Clin Infect Dis 26 389-392.
11. WK Yih, EA Silva, J Ida, et al. (1999) Bordetella holmesii-like organisms isolated from Massachusetts patients with pertussis-like symptoms. Emerg Infect Dis 5 441-443.
12. JL Guthrie, AV Robertson, P Tang, et al. (2010) Novel duplex real-time detects Bordetella holmesii in specimens from patients with pertussis-like symptoms in Ontario, Canada. J Clin Microbiol 48 1435-1437.
13. MI Panagopoulos, M Saint Jean, D Brun, et al. (2010) Bordetella holmesii bacteremia in asplenic children: report of four cases initially misidentified as Acinetobacter ewoffi. J Clin Microbiol 48 3762-3764.
14. CW Shepard, MI Daneshvar, RM Kaiser, et al. (2004) Bordetella holmesii bacteremia: a newly recognized clinical entity among asplenic patients. Clin Infect Dis 38 799-804.
15. CH Von Konig, H Rott, H Bogaerts, et al. (1998) A serologic study of organisms possibly associated with pertussis-like coughing. Pediatr Infect Dis J 17 645-649.
16. SF Davis, RW Sutter, PM Strebel, et al. (1995) Concurrent outbreaks of pertussis and Mycoplasma pneumoniae infection: clinical and epidemiological characteristics of illnesses manifested by cough. Clin Infect Dis 20 621-628.
17. K Hagiwara, K Ouchi, N Tashiro, et al. (1999) An epidemic of a pertussis-like illness caused by Chlamydia pneumoniae. Pediatr Infect Dis J 18 271-275.
18. NJ Binkin, S Salmaso, AE Tozzi, et al. (1992) Epidemiology of pertussis in a developed country with low vaccination coverage: the Italian experience. Pediatr Infect Dis J 11 653-661.
19. U Heininger, JD Cherry, T Eckhardt, et al. (1993) Clinical and laboratory diagnosis of pertussis in the regions of a large vaccine efficacy trial in Germany. Pediatr Infect Dis J 12 505-509.
20. SA Halperin, R Bortolussi, D MacLean, et al. (1989) Persistence of pertussis in an immunized population: results of the Nova Scotia Enhanced Pertussis Surveillance Program. J Pediatr 115 686-693.
21. JD Cherry, PA Brunell, GS Golden, et al. (1988) Report of the task force on pertussis and pertussis immunization – 1988. Pediatrics 81(Suppl), 939-984.
22. Centers for Disease Control and Prevention (2006) Preventing tetanus, diphtheria and pertussis among adolescents: use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccines: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 55(RR-2), 1-35.
23. MM Cortese, AL Baughman, R Zhang, et al. (2008) Pertussis hospitalizations among infants. Pediatrics 121 484-492.
24. M Falcon, M Rafael, C Garcin, et al. (2010) Increasing infant pertussis hospitalization and mortality in south Texas, 1996 to 2006. Pediatr Infect Dis J 29 265-269.
25. RW Sutter and SL Cochi (1992) Pertussis hospitalizations and mortality in the United States, 1985–1988: evaluation of the completeness of national reporting. JAMA 267 386-391.
26. Centers for Disease Control and Prevention (2005) Pertussis – United States, 2001–2003. MMWR Morb Mortal Wkly Rep 54 1283-1286.
27. P Strebel, J Nordin, K Edwards, et al. (2001) Population-based incidence of pertussis among adolescents and adults, Minnesota, 1995–1996. J Infect Dis 183 1353-1359.
28. JI Ward, JD Cherry, S-J Chang, et al. (2005) Efficacy of an acellular pertussis vaccine among adolescents and adults. N Engl J Med 353 1-9.
29. M Brennen, P Strebel, H George, et al. (2000) Evidence for transmission of pertussis in schools, Massachusetts, 1996: epidemiologic data supported by pulsed-field gel electrophoresis studies. J Infect Dis 181 210-215.
30. D Guris, PM Strebel, B Bardenheier, et al. (1999) Changing epidemiology of pertussis in the United States: increasing reported incidence among adolescents and adults, 1990–1996. Clin Infect Dis 28 1230-1237.
31. Centers for Disease Control and Prevention (2004) School-associated pertussis outbreak: Yauapai County, Arizona, September 2002–February 2003. MMWR Morb Mortal Wkly Rep 53 216-219.
32. JP Davis (2005) Clinical and economic effects of pertussis outbreaks. Pediatr Infect Dis J 24 S109-S116.
33. N Khetsuriani, K Bisgard, DR Prevots, et al. (2001) Pertussis outbreak in an elementary school with high vaccination coverage. Pediatr Infect Dis J 20 1108-1112.
34. JM Glanz, DL McClure, DJ Magid, et al. (2009) Parental refusal of pertussis vaccination is associated with an increased risk of pertussis infection in children. Pediatrics 123 1446-1451.
35. SB Omer, DA Salmon, WA Prenstein, et al. (2009) Vaccine refusal, mandatory immunization, and the risks of vaccine-preventable diseases. N Engl J Med 360 1981-1988.
36. B Ntezayabo, G De Serres and B Duval (2003) Pertussis resurgence in Canada largely caused by a cohort effect. Pediatr Infect Dis J 22 22-27.
37. CM Healy, FM Munoz, MA Rench, et al. (2004) Prevalence of pertussis antibodies in maternal delivery, cord, and infant serum. J Infect Dis 190 335-340.
38. N Wortis, PM Strebel, M Wharton, et al. (1996) Pertussis deaths: report of 23 cases in the United States, 1992 and 1993. Pediatrics 97 607-612.
39. KM Bisgard, FB Pascual, KR Ehresmann, et al. (2004) Infant pertussis: who was the source? Pediatr Infect Dis J 23 985-990.
40. LD Senzilet, SA Halperin, JS Spika, et al. (2001) Pertussis is a frequent cause of prolonged cough illness in adults and adolescents. Clin Infect Dis 32 1691-1697.
41. G DeSerres, R Shadmani, B Duval, et al. (2000) Morbidity of pertussis in adolescents and adults. J Infect Dis 182 174-179.
42. GM Lee, S Lett, S Schauer, et al. (2004) Societal costs and morbidity of pertussis in adolescents and adults. Clin Infect Dis 39 1572-1580.
43. AM Wendelboe, E Njamkepo, A Bourillon, et al. (2007) Transmission of Bordetella pertussis to young infants. Pediatr Infect Dis J 26 293-299.
44. Committee on Infectious Diseases, American Academy of Pediatrics (2006) Prevention of pertussis among adolescents: recommendations for use of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) vaccine. Pediatrics 117 965-978.
45. Centers for Disease Control and Prevention (2010) Notes from the field: Pertussis – California, January–June, 2010. MMWR Morbid Mortal Wkly Rep 59 817.
46. SS Long, CJ Welkon and JL Clark (1990) Widespread silent transmission of pertussis in families: antibody correlates of infection and symptomatology. J Infect Dis 161 480-486.
47. J Mertsola, O Ruuskanen, E Eerola and MK Viljanen (1983) Intrafamilial spread of pertussis. J Pediatr 103 359-363.
48. PN Baptista, V Magalhaes, LC Rodrigues, et al. (2007) Pertussis vaccine effectiveness in reducing clinical disease, transmissibility and proportion of cases with a positive culture after household exposure in Brazil. Pediatr Infect Dis J 25 844-846.
49. J Taranger, B Trollfors, T Lagergard, et al. (2000) Correlation between pertussis toxin IgG antibodies to postvaccination sera and subsequent protection against pertussis. J Infect Dis 181 1010-1013.
50. NN Minh, Q He, K Edelman, et al. (1999) Cell-mediated immune responses to antigens of Bordetella pertussis and protection against pertussis in school children. Pediatr Infect Dis J 18 366-370.
51. T Tomoda, H Ogura and T Kurashige (1992) The longevity of the immune response to filamentous hemagglutinin and pertussis toxin in patients with pertussis in a semiclosed community. J Infect Dis 166 908-910.
52. K Edelman, Q He, J Mäkinen, et al. (2007) Immunity to pertussis 5 years after booster immunization during adolescence. Clin Infect Dis 44 1271-1277.
53. Q He, MK Viljanen, S Nikkari, et al. (1994) Outcomes of Bordetella pertussis infection in different age groups of an immunized population. J Infect Dis 170 873-877.
54. SS Long, HL Lischner, A Deforest, et al. (1990) Serologic evidence of subclinical pertussis in immunized children. Pediatr Infect Dis J 9 700-705.
55. JD Cherry, S-J Chang, D Klein, et al. (2004) Prevalence of antibody to Bordetella pertussis antigens in serum specimens obtained from 1793 adolescents and adults. Clin Infect Dis 39 1715-1718.
56. JL Ey, B Duncan, LL Barton, et al. (1991) The influence of preschool pertussis immunization on an epidemic of pertussis. Pediatr Infect Dis J 10 576-578.
57. JL Altomar, AC Reboli, JE Mortensen, et al. (2000) Epidemiologic and molecular relatedness of Bordetella isolates from children with pertussis over a 12 year period in a single geographic area (abstract 1508). Pediatr Res 47 256A.
58. KM Bisgard, CDC Christie, SF Reising, et al. (2001) Molecular epidemiology of Bordetella pertussis by pulsed-field gel electrophoresis profile: Cincinnati, 1989–1996. J Infect Dis 183 1360-1367.
59. FR Mooi (2010) Bordetella pertussis and vaccination: the persistence of a genetically monomorphic pathogen. Infect Gen Evol 10 36-49.
60. H Hallander, A Advani, M Riffelmann, et al. (2007) Bordetella pertussis strains circulating in Europe in 1999 to 2004 as determined by pulsed-field gel electrophoresis. J Clin Microbiol 45 3257-3262.
61. EL Hewlett (1999) A commentary on the pathogenesis of pertussis. Clin Infect Dis 28(Suppl. 2), S94-S98.
62. Long SS, Fisher MC. Mortality and morbidity from pertussis in young infants (abstract 555). In: Abstracts of the 30th Interscience Conference on Antimicrobial Agents and Chemotherapy, Atlanta, GA, October 22–25, 1990.
63. LK Mikelova, SA Halperin, D Scheifele, et al. (2003) Members of the Immunization Monitoring program, Active (IMPACT). Predictors of death in infants hospitalized with pertussis: a case-control study of 16 pertussis deaths in Canada. J Pediatr 143 576-581.
64. SC van Amersfoorth, LM Schouls, HG van der Heide, et al. (2005) Analysis of Bordetella pertussis populations in European countries with different vaccination policies. J Clin Microbiol 43 2837-2843.
65. FR Mooi, IH van Loo, M van Gent, et al. (2009) Bordetella pertussis strains with increased toxin production associated with pertussis resurgence. Emerg Infect Dis 15 1206-1213.
66. E Komatsu, F Yamaguchi, A Abe, et al. (2010) Synergistic effect of genotype changes in pertussis toxin and pertactin on adaptation to an acellular pertussis vaccine in the murine intranasal challenge model. Clin Vaccine Immunol 17 80-812.
67. A Elomar, Q He, NN Minh, et al. (2009) Pertussis before and after the introduction of acellular pertussis vaccines in Finland. Vaccine 27 5443-5449.
68. CR Vitek, FB Pascual, AL Baughman, et al. (2003) Increase in deaths from pertussis among young infants in the United States in the 1990s. Pediatr Infect Dis J 22 628-634.
69. NB Halasa, FE Barr, JE Johnson, et al. (2003) Fatal pulmonary hypertension associated with pertussis in infants: does extracorporeal membrane oxygenation have a role? Pediatrics 112 1274-1278.
70. ID Daskalaki, P Hennessey, R Hubler and SS Long (2007) Resource consumption in the infection control management of pertussis exposure among healthcare workers in pediatrics. Infect Control Hosp Epidemiol 28 412-417.
71. KM Farizo, SL Cochi and ER Zell (1992) Epidemiological features of pertussis in the United States, 1980–1989. Clin Infect Dis 14 708-719.
72. WK Yih, SM Lett, FN des Vignes, et al. (2000) The increasing incidence of pertussis in Massachusetts adolescents and adults, 1989–1998. J Infect Dis 182 1409-1416.
73. PM Strebel, SL Cochi, KM Farizo, et al. (1993) Pertussis in Missouri: evaluation of nasopharyngeal culture, direct fluorescent antibody testing, and clinical case definitions in the diagnosis of pertussis. Clin Infect Dis 16 276-285.
74. SA Halperin, E Wang, B Law, et al. (1999) Epidemiological features of pertussis in hospitalized patients in Canada, 1991–1997: report of the immunization monitoring program – Active (IMPACT). Clin Infect Dis 28 1238-1243.
75. RM Cantor, L Pipas and JB McCabe (1990) Emergency department evaluation of etiology of pediatric cardiac arrest: the role of postmortem cultures. Pediatr Emerg Med 6 221.
76. A Nicoll and A Gardner (1988) Whooping cough and unrecognized postperinatal mortality. Arch Dis Child 63 41-47.
77. C Lindgren, J Milerad and H Lagercrantz (1997) Sudden infant death and prevalence of whooping cough in the Swedish and Norwegian communities. Eur J Pediatr 156 405-409.
78. U Heininger, WJ Kleemann and J Cherry (2004) D, for the Sudden Infant Death Syndrome Study Group. A controlled study of the relationship between Bordetella pertussis infections and sudden unexpected deaths among German infants. Pediatrics 114 e9-e15.
79. D Bejuk, J Begovac, A Bace, et al. (1995) Culture of Bordetella pertussis from three upper respiratory tract specimens. Pediatr Infect Dis J 14 64-65.
80. M Riffelmann, CHW von Konig, V Caro, et al. (2005) Nucleic acid amplification tests for diagnosis of Bordetella infections. Clin Microbiol 43 4925-4929.
81. F Lievano, MA Reynolds, AL Waring, et al. (2002) Issues associated with and recommendations for using PCR to detect outbreaks of pertussis. Clin Microbiol 77 2801-2805.
82. G Schlapfer, JD Cherry, U Heininger, et al. (1995) Polymerase chain reaction identification of Bordetella pertussis infections in vaccinees and family members in a pertussis vaccine efficacy trial in Germany. Pediatr Infect Dis 14 209-214.
83. MJ Sotir, DL Cappozzo, DM Warshauer, et al. (2007) Evaluation of polymerase chain reaction and culture for diagnosis of pertussis in the control of a county-wide outbreak focused among adolescents and adults. Clin Infect Dis 44 1216-1219.
84. A van der Zee, C Agterberg, M Peeters, et al. (1996) A clinical validation of Bordetella pertussis and Bordetella parapertussis polymerase chain reaction: comparison with culture and serology using samples from patients with suspected whooping cough from a highly immunized population. J Pediatr Infect Dis 174 89-96.
85. CV Guiso, C Alberti, S Liguori, et al. (2009) Proficiency program for real-time PCR diagnosis of Bordetella pertussis infections in French hospital laboratories and at the French National Reference Center for Whooping Cough and other bordetelloses. J Clin Microbiol 47 3197-3203.
86. Centers for Disease Control and Prevention (2007) Outbreaks of respiratory illness mistakenly attributed to pertussis – New Hampshire, Massachusetts, and Tennessee 2004–2006. MMWR Morb Mortal Wkly Rep 56 837-842.
87. AL Baughman, KM Bisgard, KM Edwards, et al. (2004) Establishment of diagnostic cutoff points for levels of serum antibodies to pertussis toxin, filamentous hemagglutinin, and fimbriae in adolescents and adults in the United States. Clin Diagn Lab Immunol 11 1045-1053.
88. M Gordon, HD Davies and R Gold (1994) Clinical and microbiologic features of children presenting with pertussis to a Canadian pediatric hospital during an eleven-year period. Pediatr Infect Dis J 13 617-622.
89. Centers for Disease Control and Prevention (2002) Pertussis deaths – United States, 2000. MMWR Morb Mortal Wkly Rep 51 616-618.
90. C Smith and H Vyas (2000) Early infantile pertussis, increasingly prevalent and potentially fatal. Eur J Pediatr 159 898-900.
91. E Elliott, P McIntyre, G Ridley, et al. (2004) National study of infants hospitalized with pertussis in the acellular vaccine era. Pediatr Infect Dis J 23 246-252.
92. CD Paddock, GN Sanden, JD Cherry, et al. (2008) Pathology and pathogenesis of fatal Bordetella pertussis infection in infants. Clin Infect Dis 47 328-338.
93. JE Mortensen and GL Rodgers (2000) In vitro activity of gemifloxacin and other antimicrobial agents against isolates of Bordetella pertussis and Bordetella parapertussis. J Antimicrob Chemother 45(Suppl. 1), S47-S49.
94. B Lee (2000) Progressive respiratory distress in an infant treated for presumed pertussis. Pediatr Infect Dis J 19(475), 492-493.
95. KE Wilson, PK Cassiday, T Popovic, et al. (2002) Bordetella pertussis isolates with a heterogeneous phenotype for erythromycin resistance. Clin Microbiol 40 2942-2944.
96. JM Bartkus, BA Juni, K Ehresmann, et al. (2003) Identification of a mutation associated with erythromycin resistance in Bordetella pertussis: implications for surveillance of antimicrobial resistance. Clin Microbiol 41 1167-1172.
97. T Tiwari, TV Murphy, J Moran, et al. (2005) National Immunization Program. Centers for Disease Control and Prevention. Recommended antimicrobial agents for treatment and postexposure prophylaxis of pertussis. MMWR Recomm Rep 54(RR-14), 1-13.
98. American Academy of Pediatrics (2009) Pertussis. LK Pickering,(Eds) Red Book: 2009 Report of the Committee on Infectious Diseases 28th ed Elk Grove Village, IL: American Academy of Pediatrics 504-519.
99. MA Honein, LJ Paulozzi, IM Himelright, et al. (1999) Infantile hypertrophic pyloric stenosis after pertussis prophylaxis with erythromycin: a case review and cohort study. Lancet 354 2101-2105.
100. BE Mahon, MB Rosenman and MB Kleiman (2001) Maternal and infant use of erythromycin and other macrolide antibiotics as risk factors for infantile hypertrophic pyloric stenosis. J Pediatr 139 380-384.
101. DS Friedman, CR Curtis, SL Schauer, et al. (2004) Surveillance for transmission and antibiotic adverse events among neonates and adults exposed to a healthcare worker with pertussis. Infect Control Hosp Epidemiol 25 967-973.
102. W Marrison (2007) Infantile hypertrophic pyloric stenosis in infants treated with azithromycin. Pediatr Infect Dis J 26 186-188.
103. I Krantz, SR Norrby and B Trollfors (1985) Salbutamol vs. placebo for treatment of pertussis. Pediatr Infect Dis J 4 638-640.
104. M Granstrom, AM Olinder-Nielsen, P Holmbold, et al. (1991) Specific immunoglobulin for treatment of whooping cough. Lancet 338 1230-1233.
105. SA Halperin, W Vaudry, FD Boucher, et al. (2007) Is pertussis immune globulin efficacious for the treatment of hospitalized infants with pertussis? No answer yet. Pediatr Infect Dis J 26 79-81.
106. MJ Romano, MD Weber, ME Weisse, et al. (2004) Pertussis pneumonia, hypoxemia, hyperleukocytosis, and pulmonary hypertension: improvement in oxygenation after a double volume exchange transfusion. Pediatrics 114 e264-266.
107. AF Donoso, PI Cruces, JF Camacho, et al. (2006) Exchange transfusion to reverse severe pertussis-induced cardiogenic shock. Pediatr Infect Dis J 25 846-848.
108. MJ Grzeszczak, KB Churchwell, KM Edwards and J Pietsch (2006) Leukopheresis therapy for severe infantile pertussis with myocardial and pulmonary failure. Pediatr Crit Care Med 7 580-582.
109. M Martinez, I Rochat, R Corbelli, et al. (2011) Early blood exchange transfusion in malignant pertussis: a case report. Pediatr Crit Care Med 12 e107-109.
110. HE Rowlands, AP Goldman, K Harrington, et al. (2010) Impact of rapid leukodepletion on the outcome of severe clinical pertussis in young infants. Pediatrics 126 e816-827.
111. S Soares, G Rocha, S Pissarra, et al. (2008) Pertussis with severe pulmonary hypertension in a newborn with good outcome: case report. Rev Port Pneumol 14 687-692.
112. Centers for Disease Control and Prevention (2006) Preventing tetanus, diphtheria and pertussis among adults: toxoid, reduced use of tetanus diphtheria toxoids and acellular pertussis vaccine. MMWR Recomm Rep 55(RR-17), 1-33.
113. Centers for Disease Control and Prevention www.cdc.gov/vaccines/recs/provisional/downloads/use-of-Tdao-in-hcp.pdf Accessed December 2, 2011 ACIP provisional recommendations, February 23, 2011
114. M Granstrom, G Sterner and CE Nord (1987) Use of erythromycin to prevent pertussis in newborns of mothers with pertussis. J Infect Dis 155 1210-1214.
115. JW Bass (1986) Erythromycin for treatment and prevention of pertussis. Pediatr Infect Dis 5 154-157.
116. MA Sprauer, SL Cochi, ER Zell, et al. (1992) Prevention of secondary transmission of pertussis in households with early use of erythromycin. Am J Dis Child 146 177-181.
117. G DeSerres, N Boulianne, B Duval, et al. (1995) Field effectiveness of erythromycin prophylaxis to prevent pertussis within families. Pediatr Infect Dis J 14 969-975.
118. CD Christie, AM Glover, MJ Whike, et al. (1995) Containment of pertussis in the regional pediatric hospital during the greater Cincinnati epidemic of 1993. Infect Control Hosp Epidemiol 16 556-563.
119. A Ward, J Caro, L Bassinet, et al. (2005) Health and economic consequences of an outbreak of pertussis among healthcare workers in a hospital in France. Infect Control Hosp Epidemiol 26 288-292.
120. JF Gehanno, M Pestel-Caron, M Nouvellon, et al. (1999) Nosocomial pertussis in healthcare workers from a pediatric emergency unit in France. Infect Control Hosp Epidemiol 20 549-552.
121. DJ Weber and WA Rutala (2001) Pertussis: a continuing hazard for healthcare facilities. Infect Control Hosp Epidemiol 22 736-740.
122. A Calugar, IR Ortega-Sanchez, T Tiwari, et al. (2006) Nosocomial pertussis: costs of an outbreak and benefits of vaccinating healthcare workers. Clin Infect Dis 42 981-988.
123. KB Kirkland, EA Talbot, MD Decker and KM Edwards (2009) Kinetics of pertussis immune responses to tetanus- diphtheria- acellular pertussis vaccine in health care personnel: implications for outbreak control. Clin Infect Dis 49 584-587.
124. Centers for Disease Control and Prevention (2011) Updated recommendations for use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis (Tdap) vaccine from the Advisory Committee on Immunization Practices, 2010. MMWR Morb Mortal Wkly Rep 60 13-15.
125. American Academy of Pediatrics, Committee on Infectious Diseases. Additional recommendations for use of tetanus toxoid, reduced-content diphtheria toxoid and acellular pertussis vaccine (Tdap). Pediatrics 2011;128:809–812.
126. L Gustafsson, HO Hallander, P Olin, et al. (1996) A controlled trial of a two-component acellular, a five-component acellular, and a whole-cell pertussis vaccine. N Engl J Med 334 349-355.
127. H-J Schmitt, CH Wirsing von Konig, A Neiss, et al. (1996) Efficacy of acellular pertussis vaccine in early childhood after household exposure. JAMA 275 37-41.
128. SC Wei, K Tatti, K Cushing, et al. (2010) Effectiveness of adolescent and adult tetanus, reduced-dose diphtheria, and acellular pertussis vaccine against pertussis. Clin Infect Dis J 51 315-321.
129. C Rank, HE Quinn and PB McIntyre (2009) Pertussis vaccine effectiveness after mass immunization of high school students in Australia. Pediatr Infect Dis J 28 152-153.
130. GM Lee, C LeBaron, TV Murphy, et al. (2005) Pertussis in adolescents and adults: should we vaccinate? Pediatrics 115 1675-1684.
131. KW Purdy, JW Hay, MF Botteman, et al. (2004) Evaluation of strategies for use of acellular pertussis vaccine in adolescents and adults: a cost–benefit analysis. Clin Infect Dis 39 20-28.
132. MV Gerhie and TQ Tan (2009) Pertussis disease in new mothers: effect on young infants and strategies for prevention. Obstet Gynecol 113 399-401.
133. SC deGreeff, FR Mooi, A Westerhof, et al. (2010) Pertussis disease burden in the household: how to protect young infants. Clin Infect Dis 50 1339-1345.
134. U Heininger, M Riffelmann, B Leineweber and CHW von Koenig (2009) Maternally derived antibodies against Bordetella pertussis antigens pertussis toxin and filamentous hemagglutinin in preterm and full-term newborns. Pediatr Infect Dis J 28 443-445.
135. Centers for Disease Control and Prevention (2008) Prevention of pertussis, tetanus, and diphtheria among pregnant and postpartum women and their infants: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morbid Mortal Wkly Rep 57(RR-4), 1-51.
136. Centers for Disease Control and Prevention (2011) Updated recommendations for use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine (Tdap) in pregnant women and persons who have or anticipate having close contact with an infant aged <12 months: Advisory Committee on Immunization Practices (ACIP). MMWR Morbid Mortal Wkly Rep 60 1424-1426.
137. M Wiese-Posselt and W Hellenbrand (April 22, 2010) Changes to the varicella and pertussis immunization schedule in Germany 2009: background rationale and implementation. http://www.eurosurveillance.org 15(16)
138. J Mertsola, O vander Meeren, Q He, et al. (2010) Decennial administration of a reduced antigen content diphtheria and tetanus toxoids and acellular pertussis vaccine in young adults. Clin Infect Dis 51 656-662.
139. EB Walter, N Alfred, B Rowe-West, et al. (2009) Cocooning infants: Tdap immunization for new parents in the pediatric office. Acad Pediatr 9 344-347.
140. CM Healy, MA Rench, LA Costagnini and CJ Baker (2009) Pertussis immunization in a high-risk postpartum population. Vaccine 27 5599-5602.
141. AM Dylag and SI Shah (2008) Administration of tetanus, diphtheria, and acellular pertussis vaccine to parents of high-risk infants in the neonatal intensive care unit. Pediatrics 122 e550-555.
142. NB Halasa, A O'Shea, JR Shi, et al. (2008) Poor immune responses to a birth dose of diphtheria, tetanus, and acellular pertussis vaccine. J Pediatr 153 327-332.
143. M Knuf, H-J Schmitt, J Wolter, et al. (2008) Neonatal vaccination with an acellular pertussis vaccine accelerates the acquisition of pertussis antibodies in infants. J Pediatr 152 655-660.
144. M Knuf, H-J Schmitt, J-M Jacquet, et al. (2010) Booster vaccination after neonatal priming with acellular pertussis vaccine. J Pediatr 156 675-678.
145. N Wood, P McIntyre, H Marshall and D Robertson (2010) Acellular pertussis vaccine at birth and one month induces antibody responses by two months of age. Pediatr Infect Dis J 29 209-215.
146. Hardy-Fairbanks AJ, Pan SJ, Johnson DR, Bernstein HH. Immune responses in infants following receipt of pertussis immunization by their mothers during pregnancy. 48th Annual Meeting IDSA, Vancouver, CA, October 23, 2010 (Abstract LB-54).
147. S Berkovic, L Harkin, JM McMahon, et al. (2006) De-novo mutations of the sodium channel gene SCN1A in alleged vaccine encephalopathy: a retrospective study. Lancet Neurol 5 488-492.
148. F Zepp, M Knuf, P Habermehl, et al. (2006) Safety of reduced antigen content tetanus-diphtheria-acellular pertussis vaccine in adolescents as a 6th consecutive dose of acellular-pertussis containing vaccine. J Pediatr 149 603-610.
149. WK Yih, JD Nordin, M Kulldorff, et al. (2009) An assessment of the safety of adolescent and adult tetanus-diphtheria acellular pertussis (Tdap) vaccine, using active surveillance for adverse events in the Vaccine Safety Datalink. Vaccine 27 4257-4262.
150. LA Jackson, O Yu, J Nelson, et al. (2009) Risk of medically attended local reactions following diphtheria toxoid containing vaccines in adolescents and young adults: a Vaccine Safety Datalink study. Vaccine 27 4912-4916.
151. Chang SC, O’Connor PM, Woo EJ, Slade BA. Pharmacoepidemiologic assessment of adolescent and adult tetanus, diphtheria and acellular pertussis vaccine: safety surveillance from the Vaccine Adverse Reporting System (VAERS). Submitted for publication.
152. SA Halperin, L Sweet, D Baxendale, et al. (2006) How soon after a prior tetanus-diphtheria vaccination can one give adult formulation tetanus-diphtheria-acellular pertussis vaccine? Pediatr Infect Dis J 25 195-200.
153. J Beytout, O Launay, N Guiso, et al. (2009) Safety of Tdap-IPV given 1 month after Td-IPV booster in healthy young adults: a placebo controlled trial. Hum Vaccine 5 315-321.
154. Talbot EA, Brown KH, Kirkland KB, et al. The safety of immunizing with tetanus-diphtheria-acellular pertussis vaccine (Tdap) less than 2 years following previous tetanus vaccination: experience during a mass vaccination campaign of healthcare personnel during a respiratory illness outbreak. Vaccine 2010;doi:10.1016/j.vaccine. 2010.09.034 (Epub ahead of print).
155. JM Langley, G Predy, R Guasparini, et al. (2007) An adolescent-adult formulation tetanus and diphtheria toxoids adsorbed combined with acellular pertussis vaccine has comparable immunogenicty but less reactogenicity in children 4–6 years of age than a pediatric formulation acellular pertussis vaccine and diphtheria and tetanus toxoids adsorbed combined with inactivated poliomyelitis vaccine. Vaccine 25 1121-1125.
156. CU Meyer, P Habermehl, M Knuf, et al. (2008) Immunogenicity and reactogenicity of acellular pertussis booster vaccines in children: standard pediatric versus a reduced-antigen content formulation. Hum Vaccine 4 203-209.
157. MB Rennels, MA Deloria, ME Pichichero, et al. (2000) Extensive swelling after booster doses of acellular pertussis-tetanus-diphtheria vaccines. Pediatrics 105 1-6.
158. MB Rennels (2003) Extensive swelling reactions occurring after booster doses of diphtheria-tetanus-acellular pertussis vaccines. Semin Pediatr Infect Dis 14 196-198.
159. EJ Woo, DR Burwen, SN Gatumu, et al. (2003) Vaccine adverse event reporting system working group. Extensive limb swelling after immunization: reports to the Vaccine Adverse Event Reporting System. Clin Infect Dis 37 351-358.
160. MB Rennels, MA Deloria, ME Pichichero, et al. (2002) Lack of consistent relationship between quantity of aluminum in diphtheria-tetanus-acellular pertussis vaccines and rates of extensive swelling reactions. Vaccine 20 S44-S47.
161. DW Scheifele, SA Halperin, JJ Ochnio, et al. (2005) A modified vaccine reduces the rate of large injection site reactions to the preschool booster dose of diphtheria-tetanus-acellular pertussis vaccine: results of a randomized, controlled trial. Pediatr Infect Dis J 24 1059-1066.
162. MB Rennels, S Black, EJ Woo, et al. (2008) Safety of a fifth dose of diphtheria and tetanus toxoid and acellular pertussis vaccine in children experiencing extensive, local reactions to the fourth dose. Pediatr Infect Dis J 27 464-465.